EMDT_European Medical Device Technology

European Medical Device Technology, Spring 2014

Issue link: http://dc.cn.ubm-us.com/i/309870

Contents of this Issue


Page 14 of 71

emdt.co.uk European Medical Device Technology Spring 2014 | 13 difficult to get financing rounds in the amount of € 5, 10 or 15 million, but I don't believe that there are negative developments in the medtech sector. In the funds, usually different teams handle the different sectors. Sure, the budgets might be different. But, I don't see a reallocation of funds from the medical to the IT sector. On the contrary, in certain areas you can observe an increasing con- vergence of medtech and IT, for example in mobile health or imaging. Is there currently an area within medi- cal technology that is especially interest- ing for VCs? Goergen: I can't answer that in gen- eral. For HTGF, the subsector is not important. Key factors are the level of innovation and anticipated market size and need. Whether the company sells implants or a product in the field of diag- nostics is not that crucial. Compared with the United States, ven- ture capital is scarce in Europe. About a quarter of the global venture capital is invested in the San Francisco Bay Area alone. Why does this region attract so much capital? Goergen: Many VC companies have their headquarters in the Bay Area. On the other hand, there are also many interesting companies in which they can invest. So, demand and supply are rein- forcing each other mutually. An important prerequisite for risk investors are intact exit markets. If investors can sell their shares profitably, they can use the money to build a track record. A track record is important for investors in order to raise new money. The European, and especially the Ger- man, funds have had in recent years major difficulties in getting money from banks and insurance companies. In the life sciences sector, there have been a lot of IPOs during the last year in the United States, especially in biotechnology. In Europe, there are too few IPOs of life science companies? Goergen: Yes, there were not many European IPOs in the past few years. As there is little venture capital available, the companies are often structured very slim. You need to be able to get very far with the little money that is available. As a result, many companies may have very well-developed assets but do not have the structures that would be necessary to meet the expectations of public capital market participants. I think it is easier in medical technol- ogy than in biotechnology. The reason is that it is easier for medical technology companies to grow profitable, interna- tional businesses with less money. Out of the life science sectors, medtech can be described as a "defensive" sector. In cannulated medical devices and components, precision can mean the difference between life and death. And no one can match our capacity for extreme uniformity of wall thickness or consistent concentricity in hollows for reduction, or finished cannulated implants and devices. UÊ Wall thickness tolerances to ±1% UÊ Stainless, nickel base and titanium UÊ Tube conditioning — improves surface finishes and wall thickness variation UÊ Deep hole drilling, trepanning, honing, grinding and turning Visit us at MedTech Europe: June 3–5, 2014 at Booth #C79 Î ÊÌiÀ«ÀÃiÊÀÛiÊÓ]Ê7`>]ÊÊä{äÈÓÊ1-ÊUÊTÊ£°ÓäÇ°nÓ°nnÊUÊFÊ£°ÓäÇ°nÓ°nnÈÎÊUÊvJ/ÕLiÇÇÜðV ÀÊV>ÕÇ>Ìi`Êi`V>ÇÊ`iÛViÃÊÌ>ÌÊÜÇÇÊ`>}Ãi]Êi>ÇÊÀÊiÛiÊÃ>ÛiÊÇÛiÃo oÃÌ>ÀÌÊÜÌÊÌiÊÜÀÇ`ÊÇi>`iÀÊÊÃi>ÇiÃÃÊ«ÀiVÃ\ Tube Hollows International Contact Evan Spoerl to discuss your needs or get a free quote, today: 207.892.2352 or espoerl@tubehollows.com ISO 9001: 2008 Certified ES430947_EMDT1405_013.pgs 04.29.2014 03:39 UBM black yellow magenta cyan

Articles in this issue

Links on this page

Archives of this issue

view archives of EMDT_European Medical Device Technology - European Medical Device Technology, Spring 2014